Dynavax Technologies Corp. signed a deal with GlaxoSmithKline plc to develop endosomal toll-like receptor (TLR) inhibitors targeting immunoinflammatory diseases, which could potentially be worth more than $810 million for the Berkeley, Calif.-based biotech.

GAITHERSBURG, Md. - While federal advisers shared numerous opinions Tuesday with drug regulators about the types and amounts of data needed to support product labeling using biomarkers, the panelists reached no clear consensus. (BioWorld Today)